Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 10886-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#10886-1-AP, RRID:AB_2182999
- Product name
- Syndecan-3 antibody
- Antibody type
- Polyclonal
- Description
- Syndecan-3 antibody (Cat. #10886-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IF, IHC, IP, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Electrophoresis of cell membrane heparan sulfate regulates galvanotaxis in glial cells.
Prognostic significance of the expression of GFRα1, GFRα3 and syndecan-3, proteins binding ARTEMIN, in mammary carcinoma.
Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets.
No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas.
Huang YJ, Schiapparelli P, Kozielski K, Green J, Lavell E, Guerrero-Cazares H, Quinones-Hinojosa A, Searson P
Journal of cell science 2017 Aug 1;130(15):2459-2467
Journal of cell science 2017 Aug 1;130(15):2459-2467
Prognostic significance of the expression of GFRα1, GFRα3 and syndecan-3, proteins binding ARTEMIN, in mammary carcinoma.
Wu ZS, Pandey V, Wu WY, Ye S, Zhu T, Lobie PE
BMC cancer 2013 Jan 26;13:34
BMC cancer 2013 Jan 26;13:34
Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGFβ as potential targets.
van Oosterwijk JG, Meijer D, van Ruler MA, van den Akker BE, Oosting J, Krenács T, Picci P, Flanagan AM, Liegl-Atzwanger B, Leithner A, Athanasou N, Daugaard S, Hogendoorn PC, Bovée JV
The American journal of pathology 2013 Apr;182(4):1347-56
The American journal of pathology 2013 Apr;182(4):1347-56
No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas.
Reijnders CM, Waaijer CJ, Hamilton A, Buddingh EP, Dijkstra SP, Ham J, Bakker E, Szuhai K, Karperien M, Hogendoorn PC, Stringer SE, Bovée JV
The American journal of pathology 2010 Oct;177(4):1946-57
The American journal of pathology 2010 Oct;177(4):1946-57
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- A549 cells were subjected to SDS PAGE followed by western blot with 10886-1-AP(SDC3 antibody) at dilution of 1:1000
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of MCF-7 cells, using SDC3 antibody 10886-1-AP at 1:25 dilution and Rhodamine-labeled goat anti-rabbit IgG (red).
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- Immunohistochemical of paraffin-embedded human colon cancer using 10886-1-AP(SDC3 antibody) at dilution of 1:100 (under 25x lens)
- Sample type
- tissue
